Epigenetics: the fine-tuner in inflammatory bowel disease?
Epigenetics: the fine-tuner in inflammatory bowel disease?
复制标题
DOI：
10.1097/mog.0b013e328360bd12
复制
发表时间：
2013-07
影响因子：
2.5
通讯作者：
Stylianou E
中科院分区：
文献类型：
--
作者：
Stylianou E
表观遗传学研究正在改变我们对各种复杂病理条件的理解，包括癌症，自身免疫性和炎症性疾病。在这一领域的主要最新进展的选择将审查重点是重要的新兴主题，这些疾病包括炎症性肠病（IBD）。将解决的主要当前主题是表观遗传学在疾病发病机制中的作用，包括目前对DNA甲基化和组蛋白修饰的性质和功能的理解;对染色质读者及其作为选择性治疗靶点的潜力的扩大研究;表观遗传学和代谢途径之间的联系，以及对表观遗传学变化的遗传机制的新研究。表观遗传修饰在确定IBD的分子基础，以及如何这些变化可能作为微调这些肠道疾病的基因表达的最新贡献进行了讨论。过去12-18个月发表的证据表明，靶向表观遗传因子在癌症和炎症性疾病中可能有效。所有迹象表明，未来的研究将继续揭示新的表观遗传靶点和机制，这将推动IBD和其他复杂疾病的选择性表观遗传治疗的前景。
Epigenetic studies are transforming our understanding of a variety of complex pathological conditions including cancer, autoimmune and inflammatory diseases. A selection of the major recent advances in this area will be reviewed focusing on important emerging themes that are relevant to these diseases including inflammatory bowel disease (IBD). The main current themes that will be addressed are the role of epigenetics in disease pathogenesis, including current understanding of the nature and function of DNA methylation and histone modifications; the expanding research on chromatin readers and their potential as selective therapeutic targets; the connection between epigenetics and metabolic pathways, and new studies on the mechanism of heritability of epigenetic changes. The recent contribution of epigenetic modifications in defining the molecular basis of IBD and how such changes may act as fine-tuners of gene expression in these intestinal disorders are also discussed. Published evidence over the last 12–18 months indicates that targeting epigenetic factors can be efficacious in cancer and inflammatory disease. All the indications are that future research will continue to reveal new epigenetic targets and mechanisms that will advance the prospects for selective epigenetic therapy for IBD and other complex diseases.